▶주메뉴 바로가기
▶본문 바로가기
[THE INVESTOR] Celltrion took a step closer to introducing its second biosimilar product in the US with the drug regulator accepting its biologics license application for Truxima, its copy version ...
[THE INVESTOR] Ildong Pharmaceutical said on June 28 it plans to initiate clinical trials in Europe for its plant-based Alzheimer’s disease drug candidate once it gets positive results from the ongo...
[ THE INVESTOR ] Annual exports of Korean health care and cosmetics goods reached US$10.22 billion in 2016, the Ministry of Health and Welfare said on June 29. Outbound shipments of locally produc...
[ THE INVESTOR ] Green Cross will soon be ready to make its full-fledged debut in the US market, with the aim of taking a share of the world’s largest pharmaceuticals market. The Korean biopharm...
[ THE INVESTOR ] A team of Korean researchers have succeeded in finding the genetic link between a person’s brain size and language learning abilities, according to a recent study a recent study pu...
[ THE INVESTOR ] The pharmaceutical industry has been posting a consistent rise in its recruitment rate, while also showing an above-average ratio of regular workers, statistics showed on June 27. ...
[THE INVESTOR] MacroGenics indicated on June 27 it has pushed back the launch of its biobetter version of Roche’s breast cancer treatment Herceptin to 2021 due to delays in clinical trials. Margetu...
[THE INVESTOR] Celltrion is expected to post its highest quarterly revenue on rising sales of Inflectra, its copy version of the blockbuster drug Remicade, in the US, according to a local securitie...
[THE INVESTOR] Korea’s drug maker Ildong Pharmaceutical will conduct early stage clinical trials of its target cancer therapy candidate on patients with solid tumors later this year, the company s...
[THE INVESTOR] Samsung Bioepis is expected to gain approval to commercialize its copycat version of AbbVie‘s blockbuster drug Humira in Europe later this year as its biosimilar has cleared a key reg...
[THE INVESTOR] SAN DIEGO -- What if we could simply take a protein-control pill to get in sync with our circadian rhythm, curing the dreaded symptoms of jet lag once and for all? How about reversing...
[THE INVESTOR] Korea’s private equity firm IMM Investment has offloaded some of its Celltrion Healthcare stocks worth 50 billion won (US$43.84 million) ahead of a planned initial public offering in ...
[ THE INVESTOR ] The recent explosion in data generation combined with fast-improving analytic technologies are beginning to revolutionize the field of medicine and health care, bringing closer the...
[THE INVESTOR] Celltrion Healthcare, the marketing affiliate of biosimilar maker Celltrion , has avoided heavy punishment over accounting irregularities which led to a special audit, allowing the ...
[ THE INVESTOR ] The 2017 Bio International Convention officially kicked off in San Diego, California, on June 19, bringing together thousands of biotech professionals from around the world to exch...
The Investor launches weekly 'DECODED X'
[ROK-US SUMMIT] Korean firms pledge US$35b investments in US
Samsung inks deal for US$380m appliance plant in South Carolina
Samsung undisputed leader in global smartphone display market
[EXCLUSIVE] MacroGenics plans to launch Hercepin biobetter by 2021
[EXCLUSIVE] Kia has no plans to release Stonic in US
Allianz Insurance reenters Korea after 14-year hiatus
Hyundai Steel pushes quakeproof products
![[ROK-US SUMMIT] Korean firms pledge US$35b investments in US](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=152&simg=/content/image/2017/06/29/20170629001019_0.jpg&md=20170629164719)
![[EXCLUSIVE] MacroGenics plans to launch Hercepin biobetter by 2021](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=152&simg=/content/image/2017/06/27/20170627001019_0.jpg&md=20170629173658)
![[EXCLUSIVE] Kia has no plans to release Stonic in US](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=152&simg=/content/image/2017/06/27/20170627000988_0.jpg&md=20170627211834)
